Ginkgo biloba special extract in dementia with neuropsychiatric features: A randomised, placebo-controlled, double-blind clinical trial

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 1, 2007, Pages 4-11

  Napryeyenko, Oleksandr ^a   Borzenko, Irina ^a  

^a BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

Author keywords

Alzheimer's disease; EGb 761 ; Ginkgo biloba; Neuropsychiatric symptoms; Randomised controlled trial; Vascular dementia

Indexed keywords

ANXIOLYTIC AGENT; BETAHISTINE; GINKGO BILOBA EXTRACT; HYPNOTIC AGENT; PLACEBO; PSYCHOSTIMULANT AGENT; SEDATIVE AGENT;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ANGINA PECTORIS; ARTICLE; BACKACHE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DAILY LIFE ACTIVITY; DEMENTIA; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; FEMALE; GINKGO BILOBA; HEADACHE; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; NEUROPSYCHIATRY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; THERAPY; TINNITUS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 33846820304     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296579     Document Type: Article

References (48)

1. Jellinger KA. Vascular-ischemic dementia: an update. J Neural Transm. 2002;62(suppl):1-23.
2. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222.
3. Hofman A, Ott A, Breteler MMB, Bots ML, Slooter AJC, van Harskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 1997;349:151-154.
4. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Br Med J. 2001;322:1447-1451.
5. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65:545-551.
6. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:814-815.
7. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet. 2001;357:169-175.
8. Langa KM, Foster NL, Larson EB. Mixed dementia. Emerging concepts and therapeutic implications. JAMA. 2004;292:2901-2908.
9. Korczyn AD. Mixed dementia - the most common cause of dementia. Ann N Y Acad Sci. 2002;977:129-134.
10. Förstl H. Alzheimer-Plus. Int Psychogeriatr. 2003;15:7-8.
11. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, et al. Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb 761®. Proc Natl Acad Sci USA. 2002;99:12197-12202.
12. (12] Smith JV, Luo Y. Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761®. J Alzheimer's Dis. 2003;5:287-300.
13. Sastre J, Lloret A, Borrás C, Pereda J, García-Sala D, Droy-Lefaix MT, et al. Ginkgo biloba extract EGb 761® protects against mitochondrial aging in the brain and in the liver. Cell Mol Biol. 2002;48:685-692.
14. Hoyer S, Lannert H, Nöldner M, Chatterjee SS. Damaged neuronal energy metabolism and bahavior are improved by Ginkgo biloba extract (EGb 761). J Neural Transm. 1999; 106:1171-1188.
15. Költringer P, Langsteger W, Eber O. Dose-dependent hemorheological effects and microcircularoty modifications following intravenous administration of Ginkgo biloba special extract EGb 761. Clin Hemorheol. 1995;15:649-656.
16. Spinnewyn B, Blavet N, Clostre F. Effets de l'extrait de Ginkgo biloba sur un modèle d'ischémie cérébrale chez la gerbille. Press Med. 1986;15:1511-1515.
17. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283-1290.
18. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in vascular dementia: An open 22-month study. J Neurol Sci. 2002;203-204:141-146.
19. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, 4th ed. DSM-IV. Washington, DC: American Psychiatric Association; 1994.
20. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky ST. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment. Results from the Cardiovascular Health Study. JAMA. 2002;288:1475-1483.
21. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JCS. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708-714.
22. Chan DC, Kasper JD, Black BS, Rabins PV. Prevalence and correlates of behavioral and psychiatric symptoms in community-dwelling elders with dementia or mild cognitive impairment: the Memory and Medical Care Study. Int J Geriatr Psychiatry. 2003;18:174-182.
23. [23) Cummings JL. The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology. 1997; 48(Suppl 6):S10-S16.
24. Ernst E, Pittler MH. Ginkgo biloba for vascular dementia and Alzheimer's disease: updated systematic review of double-blind, placebo-controlled, randomized trials. Perfusion. 2005; 18:388-392.
25. Hoerr R. Behavioural and psychological symptoms in dementia (BPSD): Effects of EGb 761®. Pharmacopsychiatry. 2003; 36(suppl 1):S56-S61.
26. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res. 2005;2:541-551.
27. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Good Clinical Practice: Consolidated Guideline. Geneva: ICH; 1996.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
29. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250-260.
30. Mahoney R, Johnston K, Katona C, Maxmin K, Livingston G. The TE4D-Cog: a new test for detecting early dementia in English-speaking populations. Int J Geriatr Psychiatry. 2005; 20:1172-1179.
31. Ihl R, Biesenbach A, Brieber S, Grass-Kapanke B, Salamon T. A head-to-head comparison of the sensitivity of two screening tests for dementia. Mini-Mental-State-Examination (MMSE) and the Test for the Early Detection of Dementia with Discrimination from Depression (TE4D). Psychogeriatria Polska. 2005;2:263-271.
32. Kim YS, Nibbelink DW, Overall JE. Factor structure and scoring of the SKT test battery. J Clin Psychol. 1993;49:61-71.
33. Ihl R, Grass-Kapanke B, Jänner M, Weyer G. Neuropsychometric tests in cross sectional and longitudinal studies - a regression analysis of ADAS-Cog, SKT and MMSE. Pharmacopsychiatry. 1999;32:248-254.
34. Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA et al. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc. 1989;37:725-729.
35. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
36. Bråne G, Gottfries CG, Winblad B. The GBS scale: validity, reliability and application in anti-dementia drug trials. Dement Geriatr Cogn Disord. 2001;12:1-14.
37. Rosen WG. Verbal fluency in aging and dementia. J Clin Neuropsychol. 1980;2:135-146.
38. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol. 1999;56:1388-1393.
39. Lehfeld H, Rudinger G, Rietz C, Heinrich C, Wied V, Fornazzari L, et al. Evidence of the cross-cultural stability of the factor structure of the SKT short test for assessing deficits of memory and attention. Int Psychogeriatr. 1997;9: 139-153.
40. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C, and the Galantamine USA-10 Study Group. A 5-month randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269-2276.
41. Kanowski S, Hoerr R. Ginkgo biloba extract EGb 761® in dementia: Intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry. 2003;36:297-303.
42. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF, for the North American EGb Study Group. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA. 1997;278:1327-1332.
43. Le Bars PL, Velasco FM, Ferguson JM, Dessain EC, Kieser M, Hoerr R. Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761® in Alzheimer's disease. Neuropsychobiology. 2002;45:19-26.
44. Maurer K, Ihl R, Dierks T, Frölich L. Clinical efficacy of Ginkgo biloba special extract EGb 761® in dementia of the Alzheimer type. J Psychiatr Res. 1997;31:645-655.
45. Shader R, Harmatz JS, Salzman C. A new scale for clinical assessment on geriatric populations: SANDOZ Clinical Assessment-Geriatric (SCAG). J Am Geriatr Soc. 1974;22:107-113.
46. Heinen-Kammerer T, Motzkat K, Daniel D, Gertz HJ, Koller M, Lorenz W, et al. Versorgungssituation von Demenzkranken kann durch Ginkgo biloba verbessert werden. [The situation of patients with dementia may be rectified by Ginkgo biloba.] MMW Fortschr Med (Orig). 2005;147:127-133.
47. Schneider LS, Olin JT, Lyness SA, Chui HC. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc. 1997;45:923-928.
48. Powlishta KK, Storandt M, Mandernach TA, Hogan E, Grant EA, Morris JC. Absence of effect of depression on cognitive performance in early-stage Alzheimer disease. Arch Neurol. 2004;61:1265-1268.